Gazyva (obinutuzumab) / Nippon Shinyaku, Biogen, Roche  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
URBAN, NCT04034056: Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study

Completed
N/A
299
Europe
Obinutuzumab
Hoffmann-La Roche
Follicular Lymphoma
04/24
04/24
NCT05950997: A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

Recruiting
N/A
89
RoW
Acalabrutinib, Obinutuzumab
The First Affiliated Hospital with Nanjing Medical University, AstraZeneca
Chronic Lymphocytic Leukemia
05/26
09/26
ARIADNE, NCT05326308: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

Recruiting
N/A
400
Europe
Zanubrutinib, Brukinsa®, Obinutuzumab, Gazyvaro®
iOMEDICO AG, BeiGene Switzerland GmbH
Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
04/27
04/27

Download Options